MDNA55 is an engineered circularly permuted interleukin-4 (cpIL-4) genetically fused to the catalytic domain of the bacterial pseudomonas exotoxin A (PE). The resulting fusion protein is designed such that the exotoxin is only active in the cytoplasm of the target cell following receptor-mediated endocytosis via the IL-4/IL-4R axis.

To expand on the MDNA55 opportunity, we are continuing a multi-year development program with our collaborators at CBER, USFDA to evaluate the therapeutic potential of MDNA55 for localized delivery to other CNS cancers as well as solid tumors, such as bladder cancer. We are also evaluating next generation fully human versions of MDNA55 for various non-CNS tumors known to over-express the IL-4R.